Articles from Cenna Biosciences Inc.

Cenna Biosciences Receives FDA Clearance to Begin Phase 1a/1b Clinical Trial of 8M2D, a First-in-Class Peptide Designed to Stop the Production of Amyloid in Alzheimer's Disease
Clearance advances 8M2D, designed to inhibit β-amyloid production rather than clear plaque after it forms; first participant expected to be dosed in late 2026
By Cenna Biosciences Inc. · Via ACCESS Newswire · June 17, 2026